The debate around clinical trial transparency is certainly nothing new. But is the answer, as some call for, "more transparency and oversight?"
I say it’s just not that simple.
As the former senior government official in charge of clinicaltrials.gov, I think it’s important to look at the facts – and the numbers. When it comes to the clinical trial looking glass, smart transparency must replace the smoke and mirrors currently in vogue.
Peter J. Pitts. Executive Partner for YourEncore, President - Center for Medicines in the Public Interest, Former FDA Associate Commissioner.